MedPage Today has been reporting on a variety of subjects relating to tardive dyskinesia, from clarifying terminology to the use of antipsychotic treatment. Answer these questions to see how much ...

When you’re on certain mental health medications, you have a chance of developing this disorder. Find out which symptoms to watch for and what else can increase your risk. If you take a neuroleptic ...

In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by dopamine-blocking medications. Below are some of the highlights of the year.

Researchers developed a standardized tool to assess the functional impact of tardive dyskinesia on patients. A standardized scale to assess the severity of symptoms in patients with tardive dyskinesia ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Tardive dyskinesia (TD) is a movement disorder typically caused by taking neuroleptic drugs. Treatment focuses on preventing the recurrence or persistence of symptoms. Tardive dyskinesia (TD) most ...

Neurocrine Biosciences announced positive results from its Kinect 3 study, showing that NBI-98854 achieved a statistically significant reduction in tardive dyskinesia during the six weeks of treatment ...

Tardive dyskinesia is a movement disorder that causes repetitive, involuntary movements in the face, neck, arms, and legs. The condition is a side effect of certain medications. Symptoms can improve ...

Tardive dyskinesia is a drug-induced neurological disorder characterized by involuntary movements of the face and body. The ...

Some studies suggest vitamin E may help ease symptoms of tardive dyskinesia — but how strong is the evidence, and what does it really tell us? Note: The U.S. Food and Drug Administration (FDA) does ...

Neurocrine Biosciences has submitted a marketing approval application to the Food and Drug Administration for its drug to treat tardive dyskinesia, a movement disorder. The San Diego biotech also said ...

The findings of this study align with prior research that suggests lower effective doses of clozapine are required for patients of Indian descent compared to Western populations. Switching patients of ...